A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma.
Jung Won ChunSang Myung WooSang Hyub LeeJin Ho ChoiNamyoung ParkJoo Seong KimIn Rae ChoWoo Hyun PaikWoo Jin LeeJi Kon RyuYong-Tae KimPublished in: Therapeutic advances in medical oncology (2022)
Our real-world data indicated that nal-IRI plus 5-FU/LV can be effective not only as second-line therapy, but also as third-line or later-line treatment in selected patients. Nal-IRI plus 5-FU/LV may be particularly beneficial for the survival of patients that maintain good general condition or those with favorable prior experience to irinotecan.